ArticleNature2019
Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs.
Abstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 1 pooled it
11.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
170 citing papers in PubMed, 1 synthesis or guideline pooled it, 254 citations in OpenAlex.
- Recent Advances in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumor Systemic Therapies.Current treatment options in oncology · 2025Pooled it
- Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.Nature medicine · 2026Trial
- A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Precision therapeutic strategies for advanced gastrointestinal stromal tumors.Cancer metastasis reviews · 2026Review
- Foundation model reveals the shared organization of transcription and topologically associating domains.Cell systems · 2026Article
- Rare Molecular Variants of Gastrointestinal Stromal Tumors (GISTs): Clinical Implications and Overview of Current Evidence.Targeted oncology · 2026Review
- Origins and consequences of oncogenic 3D chromatin remodelling.Nature reviews. Cancer · 2026Review
- Establishment and genomic validation of novel patient-derived xenograft models for drug discovery in gastrointestinal stromal tumor.BMC cancer · 2026Article
- CRISPR-Cas-based live cell imaging of genome dynamics.Nature reviews. Genetics · 2026Review
- Rethinking pathology image analysis through shuffling.npj biomedical innovations · 2026Article
- A transcriptional biosensor reveals mechanisms of α-ketoglutarate signaling to chromatin.Science (New York, N.Y.) · 2026Article
- Promoter reinforcement supports transcriptional resilience in drug-resistant cancer.Nature structural & molecular biology · 2026Article
- Genome-wide absolute quantification of chromatin looping.Nature structural & molecular biology · 2026Article
- Dysregulation of the PATZ1/CTCF Balance Silences ZBTB20 to Drive Melanoma Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Epigenetic modifications in cancer drug resistance: molecular mechanisms and therapeutic interventions.Molecular biomedicine · 2026Review
- Crosstalk BetweenCancers · 2026Review
- Identification of cis-regulatory elements provides insights into tissue-specific gene regulation in the sheep genome.Nature communications · 2026Article
- Succinate dehydrogenase-deficient cancer cells have increased susceptibility to Ym155-induced DNA damage.Endocrine-related cancer · 2026Article
- NSD3 stabilizes nuclear compartmentalization and promotes megabase-scale chromatin interactions.bioRxiv : the preprint server for biology · 2026Article
- Chromatin Remodeling in VSMC Phenotype Switching During Vascular Remodeling: From Mechanism to Therapeutic Potential.Biomolecules · 2026Review
110 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 1 country.
William A Flavahan *Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Yotam Drier *Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. yotam.drier@mail.huji.ac.il.
Sarah E JohnstoneDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Matthew L HemmingCenter for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Daniel R TarjanDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Esmat HegaziDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Sarah J ShareefDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Nauman M JavedDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Chandrajit P RautDepartment of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Benjamin K EschleExperimental Therapeutics Core, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Prafulla C GokhaleExperimental Therapeutics Core, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Jason L HornickDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Ewa T SicinskaDepartment of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
George D DemetriCenter for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. George_Demetri@dfci.harvard.edu.
Bradley E BernsteinDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Bernstein.Bradley@mgh.harvard.edu.
Harvard University · USDana-Farber Cancer Institute · USBroad Institute · USMassachusetts General Hospital · USBrigham and Women's Hospital · USCenter for Cancer Research · US
Funding
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MEpigenetic plasticity in tumor initiation and evolutionDP1CA216873 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BERNSTEIN, BRADLEY EVAN · 2016 to 2020
$5.9MLoss of oncogene insulation drives IDH1 mutant gliomaF32CA203153 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FLAVAHAN, WILLIAM ALEXANDER · 2016 to 2018
$178kNCI NIH HHS DP1 CA216873NCI NIH HHS F32 CA203153NIGMS NIH HHS T32 GM007753
Abstract
Epigenetic aberrations are widespread in cancer, yet the underlying mechanisms and causality remain poorly understood
Indexed as
Chromosome AberrationsAnimalsCarcinogenesisCRISPR-Cas SystemsDNA MethylationEnhancer Elements, GeneticEpigenesis, GeneticFibroblast Growth Factor 4Gastrointestinal Stromal TumorsHumansMiceMutationOncogenesProto-Oncogene Proteins c-kitReceptors, Fibroblast Growth FactorSuccinate DehydrogenaseFGF4 protein, humanFibroblast Growth Factor 4KIT protein, humanProto-Oncogene Proteins c-kitReceptors, Fibroblast Growth FactorSuccinate Dehydrogenase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.